All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Phase I study of CD20-TCB, a novel T-cell-engaging bispecific antibody, in R/R NHL
Bookmark this article
During the 25th Congress of the European Hematology Association (EHA), the Lymphoma Hub spoke to Michael Dickinson, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, AU, about the phase I study of CD20-TCB (glofitamab) in relapsed/refractory non-Hodgkin lymphoma.
CD20-TCB is a novel T-cell-engaging bispecific antibody that has demonstrated high potency in the presence of other anti-CD20 antibodies. A phase I dose-escalation study (NCT03075696), evaluating the efficacy, safety, tolerability, and pharmacokinetic profile of CD20-TCB, is currently underway. Here, Michael Dickinson outlines the high response and complete remission rates observed amongst patients receiving active doses of CD20-TCB.
Phase I study of CD20-TCB, a novel T-cell-engaging bispecific antibody, in R/R NHL
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
60 votes - 46 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox